UCB: top of the BEL, Jefferies changes to 'buy'

(CercleFinance.com) - UCB saw the biggest rally on the BEL 20 index on Thursday following an upgrade in Jefferies' analysts' recommendation, who made it their preferred share in the European midcaps biopharmaceutical sector.


In a research note published on Thursday, the analysts at Jefferies indicated that they were upgrading their recommendation on UCB to 'buy', perceiving several catalysts likely to add value.

They cite, among other things, the prospect of a marketing authorisation for Bimzelx (psoriasis) over the course of October, and encouraging phase III data in spondylarthritis and psoriatic arthritis.

Jefferies' top picks also featured the Spanish laboratory Almirall.

Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.